Vaccination with trypanosoma rangeli modulates the profiles of immunoglobulins and IL-6 at local and systemic levels in the early phase of Trypanosoma cruzi experimental infection

Memorias do Instituto Oswaldo Cruz

Volumn 106, Issue 1, 2011, Pages 32-37

  Marini, Vanina ^a,b   Moretti, Edgardo ^a,c   Bermejo, Daniela ^d   Basso, Beatriz ^a,c  

^a Laboratorio de la Coordinación Nacional de Control de Vectores   (Argentina)

^b UNIVERSIDAD CATÓLICA DE CÓRDOBA   (Argentina)

^c Facultad de Ciencias Medicas   (Argentina)

^d UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

IgG subclasses; Interleukin 6; Peritoneal fluid; Trypanosoma cruzi; Trypanosoma rangeli; Vaccination

Indexed keywords

MUS; TRYPANOSOMA; TRYPANOSOMA CRUZI; TRYPANOSOMA RANGELI;

EID: 79851473872     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762011000100005     Document Type: Article

References (33)

1. Basso B, Cervetta L, Moretti ER, Carlier Y, Truyens C 2004. Acute Trypanosoma cruzi infection: IL-12, IL-18, TNF, sTNFR and NO in T. rangeli-vaccinated mice. Vaccine 22: 1868-1872.
2. Basso B, Moretti E, Fretes R 2008. Vaccination with epimastigotes of different strains of Trypanosoma rangeli protects mice against Trypanosoma cruzi infection. Mem Inst Oswaldo Cruz 103: 370-374.
3. Basso B, Moretti ER, Domínguez M 1980. Cultivo de T. cruzi en medio monofásico con aireación para la obtención de antígenos. Medicina (Buenos Aires) 4: 428-432.
4. Basso B, Moretti ER, Vottero-Cima E 1984. Comportamiento antigénico del Trypanosoma (Schizotrypanum) cruzi y del Trypanosoma (Herpetosoma) rangeli frente a sueros de pacientes con enfermedad de Chagas. Medicina (Buenos Aires) 44: 475-479.
5. Basso B, Moretti ER, Vottero-Cima E 1987. Antigenic relationships between Trypanosoma cruzi and Trypanosoma rangeli. Rev Iber Parasitol 47: 15-21.
6. Basso B, Moretti ER, Vottero-Cima E 1991. Immune response and Trypanosoma cruzi infection in Trypanosoma rangeli-immunized mice. Am J Trop Med Hyg 44: 413-419.
7. Brodskyn CI, Silva AM, Takehara HA, Mota I 1989. IgG subclasses responsible for immune clearence in mice infected with Trypanosoma cruzi. Immunol Cell Biol 67: 343-348.
8. Capron A, Dessaint JP, Capron M, Pierce RJ 1992. Vaccine strategies against schistosomiasis. Mem Inst Oswaldo Cruz 87 (Suppl. IV): 19-27.
9. Carneiro CM, Martins-Filho OA, Reis AB, Veloso VM, Aráujo FM, Bahia MT, de Lana M, Machado-Coelho GL, Gazzinelli G, Correa-Oliveira R, Tafuri WL 2007. Differential impact of metacyclic and blood trypomastigotes on parasitological, serological and phenotypic features triggered during acute Trypanosoma cruzi infection in dogs. Acta Trop 101: 120-129.
10. Cazorla SI, Frank FM, Malchiodi EL 2009. Vaccination approaches against Trypanosoma cruzi infection. Expert Rev Vaccines 8: 921-935.
11. Cervetta L, Moretti E, Basso B 2002. Experimental Chagas' disease: the protection induced by immunization with Trypanosoma rangeli is associated with down-regulation of IL-6, TNF-α, and IL-10 synthesis. Acta Parasitol 47: 73-78.
12. Cervetta L, Moretti E, Basso B 2003a. Balance entre TNF y sus receptores solubles en la infección chagásica humana y experimental. Rev Alergia e Inmunologia Clinica 20: 61-66.
13. Cervetta L, Moretti E, Basso B, Castro I, Santamarina N 1998. Enfermedad de Chagas crónica: efectos del tratamiento en los niveles de anticuerpos hacia antígenos crudos y semipurificados del Trypanosoma cruzi. Bol Chil Parasitol 53: 3-9.
14. Cervetta L, Moretti E, Fretes R, Basso B 2003b. Vaccination with live epimastigotes of Trypanosoma rangeli protects mice against Trypanosoma cruzi lethal infection. Rev Patol Trop 32: 223-234.
15. Cordeiro FD, Martins-Filho OA, Da Costa Rocha MO, Adad SJ, Corrêa-Oliveira R, Romanha AJ 2001. Anti-Trypanosoma cruzi immunoglobulin G1 can be a useful tool for diagnosis and prognosis of human Chagas' disease. Clin Diagn Lab Immunol 8: 112-118.
16. Coura JR 2007. Chagas disease: what is known and what is needed - A background article. Mem Inst Oswaldo Cruz 102 (Suppl. I): 113-122.
17. Coura-Vital W, Carneiro CM, Martins HR, de Lana M, Veloso VM, Teixeira-Carvalho A, Bahia MT, Corrêa-Oliveira R, Martins-Filho OA, Tafuri WL, Reis AB 2008. Trypanosoma cruzi: immunoglobulin isotype profiles during the acute phase of canine experimental infection with metacyclic or blood trypomastigotes. Exp Parasitol 120: 269-274.
18. Cuba Cuba A 1998. Review of the biologic and diagnostic aspects of Trypanosoma (Herpetosoma) rangeli. Rev Soc Bras Med Trop 31: 207-220.
19. de Meis J, Morrot A, Farias-de-Oliveira DA, Villa-Verde DM, Savino W 2009. Differential regional immune response in Chagas disease. PLoS Negl Trop Dis 3: e417.
20. Fontanella GH, De Vusser K, Laroy W, Daurelio L, Nocito AL, Revelli S, Contreras R 2008. Immunization with an engineered mutant trans-sialidase highly protects mice from experimental Trypanosoma cruzi infection: a vaccine candidate. Vaccine 26: 2322-2334.
21. Gruppi A, Pistoresi-Palencia MC, Basso B, Vottero-Cima E 1990. Mouse IgE response against exoantigens of Trypanosoma cruzi. Int Arch Allergy Appl Immunol 92: 56-59.
22. Gruppi A, Pistoresi-Palencia MC, Cerban F, Vottero-Cima E 1991. Trypanosoma cruzi exoantigens: can those recognized by sera from chagasic patients trigger a protective immune response in mice? Res Immunol 142: 821-828.
23. Hoft DF, Lynch RG, Kirchhoff LV 1993. Kinetic analysis of antigen-specific immune responses in resistant and susceptible mice during infection with Trypanosoma cruzi. J Immunol 151: 7038-7047.
24. Kierszenbaum F, Moretti E, Sztein MB 1993. Molecular basis of Trypanosoma cruzi-induced immunosuppression. Altered expression by activated human lymphocytes of molecules which regulate antigen recognition and progression through the cell cycle. Biol Res 26: 197-207.
25. Minoprio P 2001. Parasite polyclonal activators: new targets for vaccination approaches? Int J Parasitol 31: 588-591.
26. Montes CL, Acosta-Rodríguez EV, Mucci J, Zuniga EI, Campetella O, Gruppi A 2006. A Trypanosoma cruzi antigen signals CD11b+ cells to secrete cytokines that promote polyclonal B cell proliferation and differentiation into antibody-secreting cells. Eur J Immunol 36: 1474-1485.
27. Parodi C, Padilla AM, Basombrío MA 2009. Protective immunity against Trypanosoma cruzi. Mem Inst Oswaldo Cruz 104 (Suppl. I): 288-294.
28. Rodrigues MM, de Alencar BC, Claser C, Tzelepis F, Silveira EL, Haolla FA, Dominguez MR, Vasconcelos JR 2009. Swimming against the current: genetic vaccination against Trypanosoma cruzi infection in mice. Mem Inst Oswaldo Cruz 104 (Suppl. I): 281-287.
29. Takehara HA, Mota I 1991. The possible mechanism of action of IgG antibodies and platelets protecting against Trypanosoma cruzi infection. Braz J Med Biol Res 24: 759-765.
30. Tarleton RL 1991. Regulation of immunity in Trypanosoma cruzi infection. Exp Parasitol 73: 106-109.
31. Umekita LF, Mota I 2000. How are antibodies involved in the protective mechanism of susceptible mice infected with T. cruzi? Braz J Med Biol Res 33: 253-258.
32. Vallejo GA, Guhl F, Carranza JC, Triana O, Pérez G, Ortiz PA, Marín DH, Villa LM, Suárez J, Sánchez IP, Pulido X, Rodríguez IB, Lozano LE, Urrea DA, Rivera FA, Cuba-Cuba C, Clavijo JA 2007. Trypanosoma rangeli parasite-vector-vertebrate interactions and their relationship to the systematics and epidemiology of American trypanosomiasis. Biomedica 27 (Suppl. 1): 110-118.
33. Vallejo GA, Guhl F, Schaub GA 2009. Triatominae-Trypanosoma cruzi/T. rangeli: vector-parasite interactions. Acta Trop 110: 137-147.